Cargando…

Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes

INTRODUCTION: Abnormalities in lipid metabolism may contribute to the development and progression of chronic kidney disease (CKD) in patients with type 2 diabetes. Fenofibrate induces early and reversible reduction in estimated glomerular filtration rate (eGFR), but it may have protective effects on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frazier, Rebecca, Mehta, Rupal, Cai, Xuan, Lee, Jungwha, Napoli, Sara, Craven, Timothy, Tuazon, Jennifer, Safdi, Adam, Scialla, Julia, Susztak, Katalin, Isakova, Tamara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6308372/ https://www.ncbi.nlm.nih.gov/pubmed/30596172 http://dx.doi.org/10.1016/j.ekir.2018.09.006

Ejemplares similares

Hospitalization Trajectories and Risks of ESKD and Death in Individuals With CKD
por: Srivastava, Anand, et al.
Publicado: (2021)

Deoxycholic Acid and Risks of Cardiovascular Events, ESKD, and Mortality in CKD: The CRIC Study
por: Frazier, Rebecca, et al.
Publicado: (2021)

Association of Educational Attainment With Incidence of CKD in Young Adults
por: Tripathy, Swetapadma, et al.
Publicado: (2020)

The Balance of the Evidence on Acid-Base Homeostasis and Progression of CKD
por: Scialla, Julia J.
Publicado: (2015)

A Patient With CKD Develops Cholestatic Liver Injury During a Clinical Trial
por: Wagener, Emma D.A., et al.
Publicado: (2017)

Emerging Role of Clinical Genetics in CKD
por: Devarajan, Prasad, et al.
Publicado: (2022)

Associations of FGF23 with 10-Year Change in eGFR and UACR and with Incident CKD in the CARDIA Cohort
por: Sunderraj, Ashwin, et al.
Publicado: (2023)

Modulation of the Association Between Age and Death by Risk Factor Burden in Critically Ill Patients With COVID-19
por: Sunderraj, Ashwin, et al.
Publicado: (2022)

Fibroblast Growth Factor 23 and Incident Cardiovascular Disease and Mortality in Middle‐Aged Adults
por: Paul, Shejuti, et al.
Publicado: (2021)

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
por: Ling, Hua, et al.
Publicado: (2013)

Benchmarking CKD: incidence of CKD in a European country with low prevalence of CKD and kidney replacement therapy
por: Ortiz, Alberto
Publicado: (2022)

Fibroblast Growth Factor 23 and Risk of Heart Failure Subtype: The CRIC (Chronic Renal Insufficiency Cohort) Study
por: Leidner, Alexander S., et al.
Publicado: (2023)

A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy
por: Strain, Joe D, et al.
Publicado: (2010)

Anticancer Properties of Fenofibrate: A Repurposing Use
por: Lian, Xin, et al.
Publicado: (2018)

Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
por: Davis, Timothy M.E.
Publicado: (2020)

Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
por: Mychaleckyj, Josyf C., et al.
Publicado: (2012)

Fibrane the reduced derivative of fenofibrate
por: Kotheimer, Amanda E., et al.
Publicado: (2019)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
por: Patel, Piyush, et al.
Publicado: (2016)

Response to Alkali Administration in Women and Men With and Without CKD
por: Pao, Alan C., et al.
Publicado: (2023)

Serum uric acid and the incidence of CKD and hypertension
por: Kuriyama, Satoru, et al.
Publicado: (2015)

Plasma Biomarkers as Risk Factors for Incident CKD
por: Sarnak, Mark J., et al.
Publicado: (2022)

Rosiglitazone and Fenofibrate Additive Effects on Lipids
por: Slim, Ahmad, et al.
Publicado: (2011)

Detecting responses to treatment with fenofibrate in pedigrees
por: Cherlin, Svetlana, et al.
Publicado: (2018)

Effect of Fenofibrate Medication on Renal Function
por: Kim, Sungjong, et al.
Publicado: (2017)

Fenofibrate-induced renal dysfunction, yes or no?
por: Emami, Fatemeh, et al.
Publicado: (2020)

The role of fenofibrate in the treatment of COVID-19
por: Yasmin, Farah, et al.
Publicado: (2021)

Vitamin D Metabolic Ratio and Risks of Death and CKD Progression
por: Bansal, Nisha, et al.
Publicado: (2019)

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
Publicado: (2005)

Low use of routine medical care among African Americans with high CKD risk: the Jackson Heart Study
por: Diamantidis, Clarissa J., et al.
Publicado: (2019)

Prediction of Incident Heart Failure in CKD: The CRIC Study
por: Zelnick, Leila R., et al.
Publicado: (2022)

Effects of fenofibrate therapy on renal function in primary gout patients
por: Li, Xinde, et al.
Publicado: (2021)

Fenofibrate: direct attenuating effects on tumor growth
por: Kapoor, Shailendra
Publicado: (2013)

Uridine Prevents Fenofibrate-Induced Fatty Liver
por: Le, Thuc T., et al.
Publicado: (2014)

Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia
por: Sun, Bing, et al.
Publicado: (2015)

Identifying fenofibrate responsive CpG sites
por: Cantor, Rita, et al.
Publicado: (2018)

Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential()()
por: Stalinska, J., et al.
Publicado: (2019)

Anti-inflammatory role of fenofibrate in treating diseases
por: Jin, Lv, et al.
Publicado: (2023)

Genetic Risk Scores Associated with Baseline Lipoprotein Subfraction Concentrations Do Not Associate with Their Responses to Fenofibrate
por: Frazier-Wood, Alexis C., et al.
Publicado: (2014)

For Better or Worse: A Niche for Notch in Parietal Epithelial Cell Activation
por: Sweetwyne, Mariya, et al.
Publicado: (2013)

The Role of Akt2 in the Protective Effect of Fenofibrate against Diabetic Nephropathy
por: Cheng, Yanli, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dmkhf3bqmslnrrd4oajfieo5nv